Disclaimer for the US market

The products and information provided on this website are intended for healthcare professionals. These products are not for sale or distribution in the United States and statements made regarding these products have not been evaluated by the U.S. Food and Drug Administration (FDA). The efficacy of these products has not been confirmed by FDA-approved research and these products are therefore not intended to diagnose, treat, cure or prevent any disease. All information presented here is for general information purposes only and not meant as a substitute for or alternative to advice from healthcare practitioners. The Federal Food, Drug and Cosmetic Act requires this notice.

Neither the Company nor its representatives is providing any medical advice, and none should be inferred, from any ideas, suggestions, testimonials or other information set forth on this website or in other Company materials or provided over the phone, in the mail, in product packaging, or in email correspondence. This website may contain links to third-party websites. The Company provides these links as a convenience only and does not endorse any of these sites. The Company is not responsible for the content of, and does not make any representations regarding the materials on, such linked third-party websites. If you decide to access or rely on information at linked third-party website, you do so at our own risk. Our terms and conditions, including disclaimers, are more fully set forth in our Terms of Use, Privacy Policy and Terms of Online Sales.

CARL. Year 1: Successful start into the marketing

After many preparations and the successfully passed CE certification, the CARL System was launched at the beginning of 2022. In addition to setting up study centers to implement the multicenter PMCF registry study, renowned reference hospitals could already be gained as CARL users in this first year. Their initial clinical expertise was already presented and published at various congresses and symposia at the end of the year. And talking about presentations: The CARL. Design and the trade fair presentations were praised by all customer-relevant emergency teams as “Strong. Technological. For rescue.”

“As a company, we have grown strongly, increased our number of employees by about a third and set up our processes and procedures for the coming years,” reports Jörg Ronde, CFO of Resuscitec GmbH. “Particularly in production, purchasing and supplier management, it was also necessary to absorb the uncertainties due to the external framework conditions and to secure our added value, which the entire team managed to do very well. In addition, we were also able to achieve the annual goals in the administrative area, which form the building blocks of the company’s future development. Thus, for example, we have established a compliance system, expanded the communication processes via website, social media and intranet, and professionalised investor relations.”

Nonetheless, after certification is before certification: At the end of the year, TÜV Süd comes for MDR certification. “We are very confident and have prepared ourselves very well to overcome this regulatory hurdle, which is particularly challenging for small companies like us,” emphasises Christoph Benk, CTO. “Likewise, we have submitted FDA pre-submission, as FDA approval is just as important to us as the further technological development of our CARL products,” says Benk. “In addition, we have successfully implemented in-house developments this year, especially in the area of production automation.”

“We as the management are proud of our team and its performance this year,” sums up Thomas Kraft, CEO. “The achievements this year give us the confidence and energy to master new challenges in the new year and to actively shape the establishment of CARL in the European area.”

< Zurück